DE60140495D1 - 1-Ä(adamantyl)alkylÜ-3-Ä(pyridinyl)alkylÜHarnstoff-Verbindungen als TNF-.alpha Hemmer zur Behandlung von Autoimmunerkrankungen - Google Patents

1-Ä(adamantyl)alkylÜ-3-Ä(pyridinyl)alkylÜHarnstoff-Verbindungen als TNF-.alpha Hemmer zur Behandlung von Autoimmunerkrankungen

Info

Publication number
DE60140495D1
DE60140495D1 DE60140495T DE60140495T DE60140495D1 DE 60140495 D1 DE60140495 D1 DE 60140495D1 DE 60140495 T DE60140495 T DE 60140495T DE 60140495 T DE60140495 T DE 60140495T DE 60140495 D1 DE60140495 D1 DE 60140495D1
Authority
DE
Germany
Prior art keywords
alkyl
tnf
adamantyl
autoimmune diseases
pyridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140495T
Other languages
English (en)
Inventor
Masakazu Ban
Hiroshi Suhara
Masato Horiuchi
Noriyoshi Yamamoto
Hiroshi Enomoto
Hiroyuki Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60140495D1 publication Critical patent/DE60140495D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60140495T 2000-05-31 2001-05-31 1-Ä(adamantyl)alkylÜ-3-Ä(pyridinyl)alkylÜHarnstoff-Verbindungen als TNF-.alpha Hemmer zur Behandlung von Autoimmunerkrankungen Expired - Lifetime DE60140495D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000162945 2000-05-31

Publications (1)

Publication Number Publication Date
DE60140495D1 true DE60140495D1 (de) 2009-12-24

Family

ID=18666780

Family Applications (4)

Application Number Title Priority Date Filing Date
DE60140495T Expired - Lifetime DE60140495D1 (de) 2000-05-31 2001-05-31 1-Ä(adamantyl)alkylÜ-3-Ä(pyridinyl)alkylÜHarnstoff-Verbindungen als TNF-.alpha Hemmer zur Behandlung von Autoimmunerkrankungen
DE60143098T Expired - Lifetime DE60143098D1 (de) 2000-05-31 2001-05-31 (Pyridinyl)alkyl-Amide oder -Harnstoffe als TNF-alpha Bildung Inhibitoren
DE60127595T Expired - Lifetime DE60127595T2 (de) 2000-05-31 2001-05-31 Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen
DE60130658T Expired - Lifetime DE60130658T2 (de) 2000-05-31 2001-05-31 Tnf-alpha-produktions-inhibitoren

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE60143098T Expired - Lifetime DE60143098D1 (de) 2000-05-31 2001-05-31 (Pyridinyl)alkyl-Amide oder -Harnstoffe als TNF-alpha Bildung Inhibitoren
DE60127595T Expired - Lifetime DE60127595T2 (de) 2000-05-31 2001-05-31 Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen
DE60130658T Expired - Lifetime DE60130658T2 (de) 2000-05-31 2001-05-31 Tnf-alpha-produktions-inhibitoren

Country Status (15)

Country Link
US (5) US7098226B2 (de)
EP (4) EP1302461B1 (de)
JP (4) JP3867196B2 (de)
KR (2) KR100978304B1 (de)
CN (3) CN1324012C (de)
AT (4) ATE448204T1 (de)
AU (3) AU6067401A (de)
CA (2) CA2409741C (de)
CY (1) CY1107089T1 (de)
DE (4) DE60140495D1 (de)
DK (1) DK1302461T3 (de)
ES (4) ES2293993T3 (de)
NO (2) NO324472B1 (de)
PT (1) PT1302461E (de)
WO (1) WO2001092229A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6067401A (en) * 2000-05-31 2001-12-11 Santen Pharmaceutical Co Ltd Tnf-alpha production inhibitors
US7741346B2 (en) * 2001-11-30 2010-06-22 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US7456222B2 (en) 2002-05-17 2008-11-25 Sequella, Inc. Anti tubercular drug: compositions and methods
CN101404986B (zh) 2002-05-17 2011-09-28 赛奎拉公司 用于诊断和治疗感染性疾病的组合物和制药方法
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
WO2005034857A2 (en) 2003-09-05 2005-04-21 Sequella, Inc. Methods and compositions comprising diamines as new anti-tubercular therapeutics
WO2005102332A1 (ja) * 2004-04-27 2005-11-03 Santen Pharmaceutical Co., Ltd. 変形性関節症治療剤
WO2005102331A1 (ja) * 2004-04-27 2005-11-03 Santen Pharmaceutical Co., Ltd. 骨粗鬆症治療剤
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006035760A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 皮膚疾患治療剤
WO2006035759A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 呼吸器疾患治療剤
WO2006043518A1 (ja) * 2004-10-18 2006-04-27 Santen Pharmaceutical Co., Ltd. 神経疾患治療剤
KR101302627B1 (ko) * 2005-01-05 2013-09-10 아비에 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
BRPI0606256A2 (pt) * 2005-01-05 2009-06-09 Abbott Lab inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos
US8562629B2 (en) * 2006-10-24 2013-10-22 Arthrocare Corporation Suture device having selective needle actuation and related method
EP1935420A1 (de) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-Butyramid Derivate als selektive 11Beta-HSD1 Inhibitoren
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
ES2431344T3 (es) * 2007-10-16 2013-11-26 Santen Pharmaceutical Co., Ltd Agente terapéutico para la vejiga hiperactiva
ES2528421T3 (es) * 2008-10-22 2015-02-09 Santen Pharmaceutical Co., Ltd Composición farmacéutica de mejor absorción a través del tracto intestinal
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
US8357939B2 (en) * 2009-12-29 2013-01-22 Siltronic Ag Silicon wafer and production method therefor
CN105934425B (zh) 2013-11-15 2020-08-07 威斯塔解剖学和生物学研究所 Ebna1抑制剂和其使用方法
SG11201708820TA (en) 2015-05-14 2017-11-29 Wistar Inst Ebna1 inhibitors and methods using same
TW201946919A (zh) 2018-05-17 2019-12-16 威斯塔研究所 Ebna1抑制劑晶形、其製備方法及其使用方法
CN110423216B (zh) * 2019-08-26 2021-01-05 浙江工业大学 一种2-(1-金刚烷甲酰胺基)乙基甲酸酯类化合物及其制备方法和应用
WO2024084056A1 (en) * 2022-10-21 2024-04-25 Etherna Immunotherapies Nv Ionizable lipids

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2640055A (en) * 1951-01-06 1953-05-26 Warner Hudnut Inc Amides
CH500979A (de) * 1967-02-16 1970-12-31 Shimamoto Takio Verfahren zur Herstellung von Pyridinmethylcarbamaten
US3682922A (en) * 1969-01-16 1972-08-08 Searle & Co N-acyl-n-{8 (n{40 ,n{40 -disubstituted amino)-alkyl{9 -1-adamantylmethylamines
US4597902A (en) 1981-05-20 1986-07-01 A. H. Robins Company, Incorporated N-(arylthioalkyl)-N'-(aminoalkyl)ureas
US4724235A (en) 1981-05-20 1988-02-09 A. H. Robins Company, Incorporated N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia
US4555515A (en) * 1985-02-25 1985-11-26 Stauffer Chemical Co. Pyridylpropyl carbamates as insect repellents
US5599944A (en) * 1987-03-24 1997-02-04 Bayer Aktiengesellschaft Intermediates for herbicidal sulphonylaminocarbonyltriazolinones having substituents which are bonded via sulphur
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
FR2664269B1 (fr) 1990-07-05 1992-10-02 Roussel Uclaf Nouveaux derives n-substitues d'alpha-mercapto alkylamines, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173506A (en) 1990-08-16 1992-12-22 Schering Corporation N-(mercaptoalkyl)ureas and carbamates
IE913855A1 (en) 1990-11-06 1992-05-22 Smithkline Beecham Corp Imidazolidinone compounds
NZ242054A (en) * 1991-03-22 1993-11-25 British Tech Group Pyridine derivatives having a bridged alicyclic group; medicaments
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
EP0757685B1 (de) * 1994-04-29 2004-07-21 Pfizer Inc. Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung
USRE39088E1 (en) * 1995-08-22 2006-05-02 Japan Tobacco, Inc. Amide compounds and use of the same
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
GB9526558D0 (en) 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
AU713676B2 (en) * 1996-01-16 1999-12-09 Merck & Co., Inc. Integrin receptor antagonists
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
CA2275478A1 (en) * 1996-12-17 1998-06-25 Kentaro Sato Piperazine compounds as inhibitors of mmp or tnf
DE59806420D1 (de) 1997-09-17 2003-01-09 Chemiefaser Lenzing Ag Verfahren zur Behandlung von Cellulosefasern
EP0903434B1 (de) 1997-09-17 2002-11-27 Lenzing Aktiengesellschaft Verfahren zur Behandlung von Cellulosefasern
CA2325741C (en) 1998-03-26 2007-05-08 Santen Pharmaceutical Co., Ltd. Urea derivatives having tnf- .alpha. production inhibitory effects
JP3603177B2 (ja) 1998-03-26 2004-12-22 参天製薬株式会社 新規ウレア誘導体
EP1103543A4 (de) 1998-08-05 2005-06-22 Santen Pharmaceutical Co Ltd Harnstoffderivate mit stickstoffhaltigen aromatischen heterocyclen
JP3472917B2 (ja) 1998-08-05 2003-12-02 参天製薬株式会社 含窒素芳香族複素環を有する新規ウレア誘導体
EP1165531A1 (de) * 1999-03-19 2002-01-02 Du Pont Pharmaceuticals Company N-adamant-1-yl-[4-chlorbenzothiazol-2-yl]harnstoff zur verwendung in der behandlung von entzündung und als antikrebs radiosensibilisierendes mittel
KR20010112408A (ko) * 1999-04-07 2001-12-20 모리타 다카카즈 Ｎ-치환되고-Ｎ'-치환된 우레아 유도체 및 ＴＮＦ-α 생성억제제로서의 그의 용도
DE29910780U1 (de) * 1999-06-21 1999-09-16 Hahn Schickard Ges Halte- und Betätigungsvorrichtung
AU6067401A (en) * 2000-05-31 2001-12-11 Santen Pharmaceutical Co Ltd Tnf-alpha production inhibitors
US7741346B2 (en) 2001-11-30 2010-06-22 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor

Also Published As

Publication number Publication date
EP1561749B1 (de) 2007-03-28
ATE448204T1 (de) 2009-11-15
EP1743885B1 (de) 2009-11-11
US7923461B2 (en) 2011-04-12
EP1568692B1 (de) 2010-09-15
ES2339141T3 (es) 2010-05-17
AU6067401A (en) 2001-12-11
KR100978304B1 (ko) 2010-08-26
EP1743885A3 (de) 2007-03-14
EP1743885A2 (de) 2007-01-17
CN1324012C (zh) 2007-07-04
EP1302461A4 (de) 2004-05-26
DE60127595T2 (de) 2008-01-10
DE60127595D1 (de) 2007-05-10
AU2001260674B2 (en) 2006-03-30
JP2006213739A (ja) 2006-08-17
KR100880698B1 (ko) 2009-02-02
CN1284771C (zh) 2006-11-15
DE60130658T2 (de) 2008-01-31
ES2353020T3 (es) 2011-02-24
JP2010059204A (ja) 2010-03-18
AU2006200864B2 (en) 2007-12-06
ES2293993T3 (es) 2008-04-01
US7098226B2 (en) 2006-08-29
JP3867196B2 (ja) 2007-01-10
ATE358122T1 (de) 2007-04-15
US20060241155A1 (en) 2006-10-26
CA2736344A1 (en) 2001-12-06
CN1590375A (zh) 2005-03-09
DE60130658D1 (de) 2007-11-08
CN1432000A (zh) 2003-07-23
US20030032623A1 (en) 2003-02-13
NO20073371L (no) 2002-11-28
JP2010059205A (ja) 2010-03-18
US7491739B2 (en) 2009-02-17
ES2284138T3 (es) 2007-11-01
EP1302461A1 (de) 2003-04-16
ATE481385T1 (de) 2010-10-15
CA2409741C (en) 2011-11-01
US20080182881A1 (en) 2008-07-31
CN1590374A (zh) 2005-03-09
DK1302461T3 (da) 2008-01-28
CN1307159C (zh) 2007-03-28
US7345064B2 (en) 2008-03-18
JP4482735B2 (ja) 2010-06-16
WO2001092229A1 (en) 2001-12-06
US20100016380A1 (en) 2010-01-21
EP1568692A1 (de) 2005-08-31
NO20025718D0 (no) 2002-11-28
NO324472B1 (no) 2007-10-29
AU2006200864A1 (en) 2006-03-23
EP1302461B1 (de) 2007-09-26
KR20030007762A (ko) 2003-01-23
KR20080093166A (ko) 2008-10-20
EP1561749A1 (de) 2005-08-10
CA2409741A1 (en) 2001-12-06
NO20025718L (no) 2002-11-28
US20060229342A1 (en) 2006-10-12
ATE374186T1 (de) 2007-10-15
DE60143098D1 (de) 2010-10-28
JP2002053555A (ja) 2002-02-19
PT1302461E (pt) 2007-12-13
CY1107089T1 (el) 2012-10-24

Similar Documents

Publication Publication Date Title
DE60140495D1 (de) 1-Ä(adamantyl)alkylÜ-3-Ä(pyridinyl)alkylÜHarnstoff-Verbindungen als TNF-.alpha Hemmer zur Behandlung von Autoimmunerkrankungen
DE602004026629D1 (de) Cyclopropanderivate und ihre pharmazeutische verwendung
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
ES2141174T3 (es) 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina.
HUP0302943A2 (hu) Új heterociklusos vegyületek, előállításuk és alkalmazásuk gyógyszerekként, különösen antibakteriális szerekként
DE60136468D1 (de) Verbindungen, die als liganden des melanocortin-rezeptors fungieren
NO179904C (no) Kondenserte heterocykliske forbindelser og deres anvendelse
MXPA02011417A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
MXPA02011418A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico.
DE69507293D1 (de) Benzamid-derivate als vasopressin-antagonisten
ATE383340T1 (de) Unsymmetrische zyklische diaminverbindung
DK0482071T3 (da) Nye antivirale midler
HK1016151A1 (en) Intermediate compounds suitable for use in the synthesis of modified oligodeoxyribonucleotides
NO20023480L (no) Fremgangsmåte for rensing av avgass-strömmer
ATE79118T1 (de) N-pyridinyl-9h-carbazol-9-amine, verfahren zu ihrer herstellung und ihre verwendung als medikamente.
ATE250027T1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
ATE117671T1 (de) Aminoketonverbindungen.
DK1049670T3 (da) Azetidincarboxamidderivater til behandling af CNS-lidelser
DK1149079T3 (da) Tetrahydroisoquinolinalkanolderivater og farmaceutiske præparater indeholdende samme
TH14160EX (th) สารยับยั้งโพรทิเอส ประเภทแอมีนไดออล
TH18165A (th) สารยับยั้งการเกิดคีโมแทกซิของอีโอซีโนฟีล
TH39469A3 (th) สารประกอบไซคลิกเอไมด์

Legal Events

Date Code Title Description
8364 No opposition during term of opposition